Why Johnson & Johnson's Strong Buy Rating Is Justified (Rating Upgrade)
Source: SeekingAlpha
2025-01-30 17:03:15 ET
Summary
- On January 22, Johnson & Johnson released financial results for the fourth quarter of 2024, which beat my expectations again.
- So, sales of its oncology franchise reached $5.5 billion, an increase of 19% compared to the fourth quarter of 2023.
- Moreover, Johnson & Johnson expects its operational sales to grow by 2% to 3% in 2025, while its adjusted diluted EPS will be between $10.50 and $10.70, implying single-digit percentage growth.
- In this article, you will learn five reasons why I believe Johnson & Johnson is an appealing stock for income-oriented investors.
Johnson & Johnson (NYSE: JNJ ) is a major player in the pharmaceutical industry, with a rich portfolio of medications widely used to treat various types of cancer, as well as autoimmune and neurological disorders....
Read the full article on Seeking Alpha
For further details see:
Why Johnson & Johnson's Strong Buy Rating Is Justified (Rating Upgrade)
Takeda Pharmaceutical Company Limited American Depositary Shares
NASDAQ: TAK
TAK Trading
-0.52% G/L:
$18.03 Last:
1,310,028 Volume:
$17.98 Open:
TAK Latest News
March 02, 2026 02:00:00 am
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
February 24, 2026 09:35:00 am
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity
TAK Stock Data
$57,107,745,653
3,115,826,299
N/A
157
N/A
Pharmaceuticals
Healthcare
JP
Chuo-ku
